← Back to all trials
Not Yet Recruiting
NCT05689164
A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
Conditions: Duchenne Muscular Dystrophy
Sex: Male
Ages: 0 Years – N/A
Phase: PHASE3
Enrollment: 250
Sponsor: Pfizer
Summary
The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec.
We are seeking participants from previous Pfizer interventional studies.
We will follow participants' experience in this study for 10 years after the end of their previous study.
Participants will have 1 annual onsite visit and a few annual remote visits.
The exact number of remote visits will be decided by their study doctor.
Eligibility Criteria
Inclusion Criteria:Participants who received fordadistrogene movaparvovec in a previous Pfizer interventional study.Exclusion Criteria:Investigator site staff directly involved in the study and their family members
Source: ClinicalTrials.gov (NCT05689164). StuddyBuddy aggregates publicly available trial information.
